Avalo Therapeutics's total assets for Q1 2025 were $138.52M, a decrease of -8.10% from the previous quarter. AVTX total liabilities were $15.91M for the fiscal quarter, a -10.12% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.